Introduction
============

Chronic granulomatous disease (CGD) is an inherited immunodeficiency characterized by recurrent severe bacterial and fungal infections. The underlying genetic defect of the phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase results in failure to produce reactive oxygen intermediates (ROI), favoring invasive infections [@bib1]. CGD is also characterized by a hyperinflammatory response following immune activation [@bib2; @bib3], which might lead to granuloma formation even in the absence of pathogen [@bib4]. A recent report proposed that impaired activation of the immunoregulatory indoleamine 2,3-dioxygenase (IDO) pathway [@bib5; @bib6; @bib7] contributed to an amplified inflammatory response in murine CGD [@bib8]. IDO, mediating tryptophan metabolism, is a heme-containing enzyme and requires posttranslational activation through the reduction of the ferric (Fe^3+^) to the ferrous (Fe^2+^) form [@bib9] before the metabolic breakdown of tryptophan along the kynurenine pathway can be initiated. Previous studies proposed an essential role for superoxide and ROI for IDO activation [@bib10; @bib11]. In consistence with this concept, IDO activity was found to be abolished in CGD mice [@bib8]. CGD (p47 phox^−/−^) (*phox*, phagocytic oxidase) mice responded to experimental *Aspergillus* infection with hyperinflammation, indicated by severe lung injury and a Th17 polarized response, and showed reversal of the hyperinflammatory phenotype upon application of the tryptophan breakdown product kynurenine.

As this finding may have significant impact on the understanding of CGD pathophysiology, we investigated whether defective IDO activation was also present in human CGD.

Methods
=======

Heparinized blood was collected after written informed consent from four CGD patients, including one with X-linked (gp91phox) and three with autosomal recessive (p47phox) inheritance ([Table 1](#tbl1){ref-type="table"}). All patients were free of infection and presented no clinical or laboratory signs of inflammation at the time of blood collection (not shown). The first diagnosis of CGD was made in all patients by \< 10% oxygen radical production, as determined by chemiluminescence, dihydrorhodamine, and/or nitroblue tetrazolium tests in PMA-stimulated phagocytes, followed by genetic analyses. Approval for this study was obtained from the institutional review board of the St. Anna Children\'s Hospital, Vienna, Austria. All patients and/or their parents gave written informed consent.

Immature dendritic cells (DCs) were generated from CGD patients and controls in parallel, as described [@bib12], and were activated with 50 ng lipopolysaccharide (LPS) (Calbiochem; *Escherichia coli* O111:B4) and 1000 U/ml interferon-gamma (IFN-γ) (Boehringer Ingelheim) for 48 hours. Following stimulation, the DC recovery rate was analyzed by flow cytometry using propidium-iodide staining. IDO protein expression was determined by immunoblotting, using a monoclonal mouse anti-human IDO antibody kindly provided by O. Takikawa (National Institute for Longevity Sciences, National Center for Geriatrics and Gerontology, Aichi, Japan) [@bib12]. IDO activity was determined measuring the release of the tryptophan breakdown product kynurenine into cell culture supernatants by high performance liquid chromatography [@bib12]. The kynurenine release by patient cells was compared to that of control cells by calculating the mean kynurenine concentration ± the standard error of the mean (SEM) in cell culture supernatants. Statistical analyses were performed using the Student\'s *t*-test (paired, two-tailed). A *p*-value \< 0.05 was considered to indicate statistical significance.

Results and discussion
======================

To analyze whether the IDO immunoregulatory pathway was impaired in human CGD, we compared the ability of IDO activation in monocyte-derived DCs obtained from CGD patients and from healthy controls. We activated immature DCs with LPS and IFN-γ for 48 hours. This strategy recapitulates to some extent inflammatory stimulation and consistently results in abundant IDO activity in human cells [@bib12].

To exclude that any difference in IDO activity in CGD patients and controls was related to an altered sensitivity to apoptosis in CGD patients, we first ascertained that the recovery rate of CGD and control DCs after activation with LPS/IFN-γ was within the same range ([Fig. 1](#fig1){ref-type="fig"}A). Likewise, upon activation, patient and control DCs developed a similarly mature phenotype, as assessed by flow cytometric staining for expression of CD83, CD80, CD86, and HLA-DR [@bib12] (not shown). Next, immunoblotting of IDO protein expression showed that LPS/IFN-γ activation of immature DCs induced comparable IDO protein expression in CGD and in control DCs ([Fig. 1](#fig1){ref-type="fig"}B). Strikingly, analyzing IDO activity, we found that abundant tryptophan catabolism was consistently inducible in DCs of CGD patients. While immature DCs did not metabolize tryptophan ([Fig. 1](#fig1){ref-type="fig"}C) [@bib12], activation of DCs obtained from CGD patients resulted in the release of 11.7 ± 4.1 µM kynurenine, and this was within the same range as that of control cells, which released 11.2 ± 0.6 µM kynurenine (*p* = 0.83) ([Fig. 1](#fig1){ref-type="fig"}C). These findings clearly demonstrate that in humans the induction of IDO enzymatic activity is not essentially dependent of ROI and that the IDO activity in CGD patients is preserved.

In accordance with our findings and contrasting the previous concept of IDO activation being dependent on superoxide and ROI [@bib10], a recent study reported that in human cells superoxide dismutase mimetics, while being able to decrease intracellular superoxide, failed to significantly alter IDO activity. Instead, cytochrome b~5~, in the presence of cytochrome P450 reductase and NADPH, was found to be sufficient for reduction of Fe^3+^-IDO to Fe^2+^-IDO, thus allowing for effective initiation of IDO-mediated tryptophan breakdown [@bib13], indicating that cytochrome b~5~ rather than superoxide plays a major role in the activation of IDO in human cells.

Yet, other ROI-dependent processes such as activation of nuclear factor-erythroid 2-related factor 2 (Nrf2), which serves as an antioxidant response element and restrains the activation of NF-κB [@bib14], might contribute to the hyperinflammatory state in some patients with CGD [@bib15].

In conclusion, this study provides clear evidence that the IDO immunoregulatory pathway is intact in human CGD despite defective NADPH oxidase function. Our findings are consistent with the observation of normal kynurenine levels in the sera of a CGD patient, who suffered from severe *Aspergillus* infection, before as well as after gene therapy when the patient was cured from this infection [@bib16]. The hyperinflammatory state in some CGD patients may be linked to an impaired immunoregulatory activity of ROI, e.g., by insufficient Nrf2 activation, or other mechanisms still to be discovered. Should kynurenine be considered as a treatment option in CGD at all the rationale for its use could be to augment rather than to replace IDO-mediated immunoregulation.
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![Normal expression and activation of IDO in DCs of human CGD patients. (A) Recovery rate of DCs after activation with LPS/IFN-γ for 48 hours as healthy control derived DCs. (B) IDO immunoblotting; note that immunoblotting of immature DCs (iDC) was not possible due to low cell numbers obtained from patients 2--4. (C) kynurenine release into cell culture supernatants; gray bars, immature DCs; black bars, DCs activated with LPS/IFN-γ for 48 hours. co, control; pt, patient; KYN, kynurenine.](gr1){#fig1}

###### 

Patient characteristics.

  Patient no.                          Sex/age       Age at diagnosis   Diagnosis   Clinical course   Treatment                                                                                                     
  ------------------------------------ ------------- ------------------ ----------- ----------------- ------------------------------------------------------------------------------------------------------------- ------------------------
  1                                    M, 5 years    2 years            CL \< 1%    p91phox           Clinically well                                                                                               Prophylactic TMP, Itra
  2^a^                                 M, 11 years   11 years           DHR 0%      p47phox           Recurrent blepharitis, recurrent skin abscesses, clinically well at blood collection                          Prophylactic TMP, Itra
  NBT 0%                                                                                                                                                                                                            
  3[a](#tblfn1){ref-type="table-fn"}   F, 8 years    8 years            DHR 11%     p47phox           Recurrent diarrhea, recurrent oral ulcers, lymphadenitis, clinically well at blood collection                 Prophylactic TMP, Itra
  NBT 0%                                                                                                                                                                                                            
  4                                    F, 12 years   6 years            DHR 0%      p47phox           Multifocal pleuropneumonia (*Burkholderia multivorans*) at age 6 years, clinically well at blood collection   None (non-compliant)
                                                                                                                                                                                                                    

Abbreviations: M, male; F, female; CL, chemiluminescence; DHR, dihydrorhodamine; NBT, nitroblue tetrazolium; TMP, trimethoprim; Itra, itraconazole.
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